A Phase 4 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Diabetic Macular Edema, sponsored by Bayer. Completed at 10 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 18th largest by enrollment, is the only one that started in 2022, is one of 26 in phase 4, and was the 47th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 1 started in 2022.
This study's enrollment of 100 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
16 studies in Macular Edema by Bayer: none open now, 1 under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Macular Edema by Bayer, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 4, and was the 12th registered.
Bayer’s Macular Edema studies by the year they started, since 2009.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
Among Bayer’s 16 in Macular Edema:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat people who have diabetic macular edema (DME).
Diabetic macular edema (DME) is a complication of diabetes. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye. Damaged blood vessels in the eye may lead to leakage of the fluid into the central part of the retina at the back of the eye (also called macula) where sharp, straight-ahead vision occurs. Fluid accumulation makes the macula swell and results in reduced vision. If not treated, DME can result in complete loss of central detailed vision.
The study treatment intravitreal aflibercept (also called BAY865321) works by blocking VEGFR-1 receptor activity. Intravitreal aflibercept is already approved in over 105 countries for doctors to prescribe to people with DME. In India, aflibercept is approved conditionally for people with DME. The reason for this is that the sponsor was asked to collect more safety data for intravitreal aflibercept in Indian people with DME.
The main purpose of this study is to collect more data to learn how safe intravitreal aflibercept is in Indian people with DME. To see how safe intravitreal aflibercept is, the researchers will collect the information/data on the medical problems the participants may have during the study, and which may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AEs). AEs will be categorized according to relatedness, seriousness, discontinuation of therapy, action taken and outcome.
The study participants will receive aflibercept as an injection directly into the space in the back of the eye once every 4 weeks in the first 5 months, followed by one injection every 8 weeks for the rest of the study duration. Only one eye per participant to be treated with aflibercept will be considered for the study.
Each participant will be in the study for approximately 52 weeks. The treatment duration will be 48 weeks. For each participant 11 visits to the study site are planned. The study team will perform additional safety calls 16 to 36 hours after each visit starting at visit 2. Alternatively, an additional safety visit can be arranged/planned for the day after treatment.
During the study, the study team will:
At the end of the study the participants will be switched to commercially available treatment if recommended by the study doctor/if the participant still benefits from the treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Received previous/ prior treatment as mentioned below:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one aflibercept injection per month (every four weeks) for five consecutive doses, followed by one injection every alternate month (every 8 weeks) for rest of the duration
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Injection, 2mg (equivalent to 50 µL solution for injection)
Frequency (Number) of Ocular and Non-ocular Treatment Emergent Adverse Events (TEAE).
Time frame: An AE arising or worsening after the start of study treatment administration until 30 days after the last administration of study treatment, up to 52 weeks.
The Change in BCVA From Baseline to Week 52, as Assessed Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart or Equivalent.
Proportion of eyes that lose ≥ 5, 10 and 15 ETDRS letters from baseline to Week 52, Overall
Time frame: From baseline to week 52
Change in Central Retinal Thickness (CRT) From Baseline to Week 52 as Measured by Optical Coherence Tomography (OCT), FA
Time frame: From baseline to week 52
Proportion of Eyes That Gained ≥ 5, 10 and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters From Baseline to Week 52
Only 1 eye per patient was enrolled in the study. Therefore, number of participants equals to number of eyes.
Time frame: From baseline to Week 52
Proportion of Eyes With a ≥2 Step Improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) Score
Only 1 eye per patient was enrolled in the study. Therefore, number of participants equals to number of eyes. The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) is a standardized tool used to measure the severity of diabetic retinopathy. The scale assesses the level of retinal damage and provides a score based on the presence of specific lesions and the extent of retinal involvement. Scale Range: * Minimum score: 10 (indicating no retinopathy) * Maximum score: 85 (indicating severe retinopathy) Interpretation of Scores: Higher scores indicate worse outcomes, reflecting more severe diabetic retinopathy
Time frame: From baseline to Week 52
The trial was planned to be conducted at approximately 10-15 study sites across India. A total of 100 patients were enrolled into the study. The study duration was up to 13 months covering 11 visits.
| Milestone | Naïve | Pre-Treated |
|---|---|---|
| Started | 105 | 16 |
| Completed | 73 | 12 |
| Not completed | 32 | 4 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Screen failure | 20 | 1 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Death | 1 | 0 |
| Milestone | Naïve | Pre-Treated |
|---|---|---|
| Started | 105 | 16 |
| Completed | 99 | 16 |
| Not completed | 6 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow up (1 participant) | 1 | 0 |
| Withdrew: Screen failure | 3 | 0 |
| Withdrew: Screen failure that was identified after screening (1 participant) | 1 | 0 |
| Milestone | Naïve | Pre-Treated |
|---|---|---|
| Started | 85 | 15 |
| Completed | 68 | 11 |
| Not completed | 17 | 4 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Physician decision | 4 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Subject did nod visit the site despite multiple follow-up | 3 | 1 |
| Withdrew: Refuse by subject | 1 | 0 |
| Withdrew: Subject did not go to the site for visit | 1 | 0 |
| Percentage of participants | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Ocular | 36.5 (26.29 to 47.62) | 60 (32.29 to 83.66) | 40 (30.33 to 50.28) |
| Non-Ocular | 21.2 (13.06 to 31.39) | 33.3 (11.82 to 61.62) | 23 (15.17 to 32.49) |
Proportion of eyes that lose ≥ 5, 10 and 15 ETDRS letters from baseline to Week 52, Overall
| Percentage of eyes | Naïve | Pre-Treated | Total |
|---|---|---|---|
| ≥ 5 ETDRS letters | 2.4 (0.3 to 8.2) | 7.1 (0.2 to 33.9) | 3 (0.6 to 8.6) |
| ≥ 10 ETDRS letters | 2.4 (0.3 to 8.2) | 0 (0.0 to 23.2) | 2 (0.2 to 7.1) |
| ≥ 15 ETDRS letters | 2.4 (0.3 to 8.2) | 0 (0.0 to 23.2) | 2 (0.2 to 7.1) |
| um | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Change in Central Retinal Thickness (CRT) From Baseline to Week 52 as Measured by Optical Coherence Tomography (OCT), FA | -203.5 ± 148.19 | -160.3 ± 127.42 | -197.4 ± 145.63 |
Only 1 eye per patient was enrolled in the study. Therefore, number of participants equals to number of eyes.
| Participants | Naïve | Pre-Treated | Total |
|---|---|---|---|
| ≥5 ETDRS letters | 76 | 11 | 87 |
| ≥10 ETDRS letters | 63 | 11 | 74 |
| ≥15 ETDRS letters | 43 | 7 | 50 |
Only 1 eye per patient was enrolled in the study. Therefore, number of participants equals to number of eyes. The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) is a standardized tool used to measure the severity of diabetic retinopathy. The scale assesses the level of retinal damage and provides a score based on the presence of specific lesions and the extent of retinal involvement. Scale Range: * Minimum score: 10 (indicating no retinopathy) * Maximum score: 85 (indicating severe retinopathy) Interpretation of Scores: Higher scores indicate worse outcomes, reflecting more severe diabetic retinopathy
| Participants | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Proportion of Eyes With a ≥2 Step Improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) Score | 12 | 3 | 15 |
Collected over An AE arising or worsening after the start of study treatment administration until 30 days after the last administration of study treatment, up to 52 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pre-treated | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| Drug Naive | 1/85 (1.2%) | 4/85 (4.7%) | 42/85 (49.4%) |
| Pre-treated (Ocular) | 0/15 (0%) | 0/15 (0%) | 9/15 (60%) |
| Drug Naive (Ocular) | 1/85 (1.2%) | 0/85 (0%) | 31/85 (36.5%) |
| Pre-treated (Non-ocular) | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| Drug Naive (Non-ocular) | 1/85 (1.2%) | 4/85 (4.7%) | 17/85 (20%) |
| Pre-treated (Study Eye) | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Drug Naive (Study Eye) | 1/85 (1.2%) | 0/85 (0%) | 12/85 (14.1%) |
| Pre-treated (Fellow Eye) | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) |
| Drug Naive (Fellow Eye) | 1/85 (1.2%) | 0/85 (0%) | 22/85 (25.9%) |
| Event | Pre-treated | Drug Naive | Pre-treated (Ocular) | Drug Naive (Ocular) | Pre-treated (Non-ocular) | Drug Naive (Non-ocular) | Pre-treated (Study Eye) | Drug Naive (Study Eye) | Pre-treated (Fellow Eye) | Drug Naive (Fellow Eye) |
|---|---|---|---|---|---|---|---|---|---|---|
| Acute coronary syndromeCardiac disorders | 0/15 | 2/85 | 0/15 | 0/85 | 0/15 | 2/85 | 0/15 | 0/85 | 0/15 | 0/85 |
| Abdominal discomfortGastrointestinal disorders | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 0/85 |
| Abdominal distensionGastrointestinal disorders | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 0/85 |
| NauseaGastrointestinal disorders | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 0/85 |
| Cerebrovascular accidentNervous system disorders | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 0/85 |
| Breast conserving surgerySurgical and medical procedures | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 1/85 | 0/15 | 0/85 | 0/15 | 0/85 |
| Event | Pre-treated | Drug Naive | Pre-treated (Ocular) | Drug Naive (Ocular) | Pre-treated (Non-ocular) | Drug Naive (Non-ocular) | Pre-treated (Study Eye) | Drug Naive (Study Eye) | Pre-treated (Fellow Eye) | Drug Naive (Fellow Eye) |
|---|---|---|---|---|---|---|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 2/15 | 1/85 | 2/15 | 1/85 | 0/15 | 0/85 | 2/15 | 1/85 | 0/15 | 0/85 |
| Macular oedemaEye disorders | 2/15 | 9/85 | 2/15 | 9/85 | 0/15 | 0/85 | 1/15 | 2/85 | 1/15 | 7/85 |
| Macular thickeningEye disorders | 2/15 | 6/85 | 2/15 | 6/85 | 0/15 | 0/85 | 1/15 | 3/85 | 1/15 | 3/85 |
| Diabetic retinopathyEye disorders | 1/15 | 2/85 | 1/15 | 2/85 | 0/15 | 0/85 | 0/15 | 0/85 | 1/15 | 2/85 |
| Visual acuity reducedEye disorders | 1/15 | 4/85 | 1/15 | 4/85 | 0/15 | 0/85 | 1/15 | 2/85 | 0/15 | 2/85 |
| Vitreous haemorrhageEye disorders | 1/15 | 2/85 | 1/15 | 2/85 | 0/15 | 0/85 | 1/15 | 0/85 | 0/15 | 2/85 |
| Epiretinal membraneEye disorders | 1/15 | 0/85 | 1/15 | 0/85 | 0/15 | 0/85 | 1/15 | 0/85 | 0/15 | 0/85 |
| Abdominal painGastrointestinal disorders | 1/15 | 0/85 | 0/15 | 0/85 | 1/15 | 0/85 | 0/15 | 0/85 | 0/15 | 0/85 |
| PyrexiaGeneral disorders | 1/15 | 2/85 | 0/15 | 0/85 | 1/15 | 2/85 | 0/15 | 0/85 | 0/15 | 0/85 |
| Febrile infectionInfections and infestations | 1/15 | 1/85 | 0/15 | 0/85 | 1/15 | 1/85 | 0/15 | 0/85 | 0/15 | 0/85 |
Safety Analysis Set (SAF): This population included all patients who received at least one dose of the study intervention. The analyses were performed on incident TEAE. An overview table provided overall incidences for patients with any TEAE, any study drug related TEAE, any serious TEAE, any serious study drug related TEAE, any TEAE leading to change of treatment regimen with aflibercept, any TEAE leading to discontinuation of aflibercept, any TEAE with outcome death.
| Age, Continuous(Years) | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Mean | 57.6 ± 9.11 | 59.4 ± 9.01 | 57.9 ± 9.07 |
| Sex: Female, Male(Participants) | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Sex — Female | 41 | 4 | 45 |
| Sex — Male | 44 | 11 | 55 |
| Race (NIH/OMB)(Participants) | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 |
| Race — Asian | 85 | 15 | 100 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Race — Black or African American | 0 | 0 | 0 |
| Race — White | 0 | 0 | 0 |
| Race — More than one race | 0 | 0 | 0 |
| Race — Unknown or Not Reported | 0 | 0 | 0 |
| Weight (kg)(kilograms (kg)) | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Mean | 64.8 ± 11.38 | 62.4 ± 11.12 | 64.5 ± 11.31 |
| Height (cm)(Centimeters (cm)) | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Mean | 161.7 ± 9.18 | 163.3 ± 8.83 | 162.0 ± 9.11 |
| Body mass Index (kg/m2)(Kilograms per meter squared (kg/m2)) | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Mean | 24.7 ± 3.63 | 23.3 ± 2.99 | 24.5 ± 3.57 |
| Number of patients with at least one medical history finding(Participants) | Naïve | Pre-Treated | Total |
|---|---|---|---|
| Diabetic retinal oedema | 83 | 15 | 98 |
| Cataract | 8 | 3 | 11 |
| Type 2 diabetes mellitus | 85 | 15 | 100 |
| Hypertension | 49 | 11 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Aug 2022 to primary completion in Apr 2024, 19 months.
Results were first posted in Sep 2025, 1 year 4 months after primary completion.
Of 63 phase 4 interventional studies under Macular Edema, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept